Your browser doesn't support javascript.
loading
Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.
Hong, Aayoung; Piva, Marco; Liu, Sixue; Hugo, Willy; Lomeli, Shirley H; Zoete, Vincent; Randolph, Christopher E; Yang, Zhentao; Wang, Yan; Lee, Jordan J; Lo, Skylar J; Sun, Lu; Vega-Crespo, Agustin; Garcia, Alejandro J; Shackelford, David B; Dubinett, Steven M; Scumpia, Philip O; Byrum, Stephanie D; Tackett, Alan J; Donahue, Timothy R; Michielin, Olivier; Holmen, Sheri L; Ribas, Antoni; Moriceau, Gatien; Lo, Roger S.
Afiliação
  • Hong A; Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Piva M; Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Liu S; Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Hugo W; Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Lomeli SH; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Zoete V; Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Randolph CE; Department of Fundamental Oncology, Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland.
  • Yang Z; Arkansas Children's Research Institute, Little Rock, Arkansas.
  • Wang Y; Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Lee JJ; Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Lo SJ; Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Sun L; Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Vega-Crespo A; Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Garcia AJ; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Shackelford DB; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Dubinett SM; Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Scumpia PO; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Byrum SD; Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Tackett AJ; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Donahue TR; Division of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Michielin O; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Holmen SL; Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Ribas A; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California.
  • Moriceau G; Department of Dermatology, Veteran's Administration Greater Los Angeles Healthcare System, Los Angeles, California.
  • Lo RS; Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Cancer Discov ; 11(3): 714-735, 2021 03.
Article em En | MEDLINE | ID: mdl-33318037
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T / Resistencia a Medicamentos Antineoplásicos / Quinases de Proteína Quinase Ativadas por Mitógeno / MAP Quinases Reguladas por Sinal Extracelular / Inibidores de Proteínas Quinases Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos T / Resistencia a Medicamentos Antineoplásicos / Quinases de Proteína Quinase Ativadas por Mitógeno / MAP Quinases Reguladas por Sinal Extracelular / Inibidores de Proteínas Quinases Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article